Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver

Hernandez‑Unzueta,Iera; Benedicto,Aitor; Olaso,Elvira; Sanz,Eduardo; Viera,Cristina; Arteta,Beatriz; Márquez,Joana

doi:10.3892/ol.2017.6016

Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver

Authors:
- Iera Hernandez‑Unzueta
- Aitor Benedicto
- Elvira Olaso
- Eduardo Sanz
- Cristina Viera
- Beatriz Arteta
- Joana Márquez
View Affiliations

Affiliations: Department Cell Biology and Histology, School of Medicine and Dentistry, Basque Country University, Leioa, E‑48940 Bizkaia, Spain, Catalysis S.L, Toledo, E‑28016 Madrid, Spain
Published online on: April 10, 2017 https://doi.org/10.3892/ol.2017.6016
Pages: 4002-4012
Copyright: © Hernandez‑Unzueta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is an aggressive disease in which patients usually die due to its metastatic progression to the liver. Up to date, irinotecan is one of the most used chemotherapeutic agents to treat CRC metastasis with demonstrated efficacy. However, the severity of the side effects constitute the main limitation to its use in the treatment. Consequently, new complementary therapies are being developed to avoid these adverse effects while maintaining the efficacy of the antitumoral drugs. Ocoxin oral solution (OOS®) is a nutritional mixture containing biologically active compounds with demonstrated antitumoral and immunomodulatory effects. Thus, we aimed to analyze the effect of OOS® as a suitable complement to irinotecan therapy in the treatment of CRC metastasis to the liver. First, the effect of OOS®, irinotecan and the combination of both on the viability of C26 cells was tested in vitro and in vivo. Second, the expression of caspase‑3, Ki67 and the macrophage infiltration by F4/80 marker was quantified in liver tissue sections by immunohistochemistry. Finally, mRNA microarray study was carried out on tumor cells isolated from tumor‑bearing livers collected from mice subjected to the above treatments. Our results show that OOS® administered as a complementary therapy to irinotecan reduced tumor cell viability in vitro. Moreover, irinotecan administered either alone or in combination with 100 µl OOS® from the 7th day after tumor cell inoculation decreased the metastatic growth in the liver. Besides, several genes with binding and catalytic activities showed to be deregulated by RNA microarray analysis. In conclusion, OOS®, when administered as a complement to irinotecan, reduced the metastatic development of colorectal cancer to the liver. Additionally, the overall health state of the animals improved. These results point out OOS® as a potential supplement to the anti-tumoral treatments used in clinical settings in patients suffering from disseminated colorectal cancer.

View Figures

View References

1	Fujita K, Kubota Y, Ishida H and Sasaki Y: Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol. 21:12234–12248. 2015. View Article : Google Scholar : PubMed/NCBI
2	Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR and Brodt P: The multifaceted role of the microenvironment in liver metastasis: Biology and clinical implications. Cancer Res. 73:2031–2043. 2013. View Article : Google Scholar : PubMed/NCBI
3	Gol'dberg ED, Amosova EN, Zueva EP, Razina TG, Krylova SG and Zorikov PS: Licorice preparations improve efficiency of chemotherapy and surgical treatment of transplanted tumors. Bull Exp Biol Med. 145:252–255. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kontek R, Drozda R, Sliwiński M and Grzegorczyk K: Genotoxicity of irinotecan and its modulation by vitamins AC and E in human lymphocytes from healthy individuals and cancer patients. Toxicol In Vitro. 24:417–424. 2010. View Article : Google Scholar : PubMed/NCBI
5	Arabski M, Kazmierczak P, Wisniewska-Jarosinska M, Poplawski T, Klupinska G, Chojnacki J, Drzewoski J and Blasiak J: Interaction of amoxicillin with DNA in human lymphocytes and H. pylori-infected and non-infected gastric mucosa cells. Chem Biol Interact. 152:13–24. 2005. View Article : Google Scholar : PubMed/NCBI
6	Hernández-Garcia S, González V, Sanz E and Pandiella A: Effect of oncoxin oral solution in HER2-overexpressing breast cancer. Nutr Cancer. 67:1159–1169. 2015. View Article : Google Scholar : PubMed/NCBI
7	Márquez J, Mena J, Hernandez-Unzueta I, Benedicto A, Sanz E, Arteta B and Olaso E: Ocoxin^® oral solution slows down tumor growth in an experimental model of colorectal cancer metastasis to the liver in balb/c mice. Oncol Rep. 35:1265–1272. 2016.PubMed/NCBI
8	Diaz-Rodriguez E, Hernández-Garcia S, Sanz E and Pandiella A: Antitumoral effect of ocoxin on acute myeloid leukemia. Oncotarget. 7:6231–6242. 2016.PubMed/NCBI
9	Mi H, Muruganujan A, Casagrande JT and Thomas PD: Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 8:1551–1566. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mi H, Poudel S, Muruganujan A, Casagrande JT and Thomas PD: PANTHER version 10: Expanded protein families and functions, and analysis tools. Nucleic Acids Res. 44(D1): D336–D342. 2016. View Article : Google Scholar : PubMed/NCBI
11	Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, Glick S, Ingrao J, Klassen-Ross T, Lacroix-Fralish ML, et al: Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 7:447–449. 2010. View Article : Google Scholar : PubMed/NCBI
12	Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, et al: Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med. 23:356–362. 2015. View Article : Google Scholar : PubMed/NCBI
13	Mikalauskas S, Mikalauskiene L, Bruns H, Nickkholgh A, Hoffmann K, Longerich T, Strupas K, Büchler MW and Schemmer P: Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids. 40:1139–1150. 2011. View Article : Google Scholar : PubMed/NCBI
14	Dayem-Uddin M, Islam M, Mahmood I, Gosh A, Khatun R and Kundu S: Findings of the 3-month supportive treatment with oncoxin solution beside the standard modalities of patients with different neoplastic diseases. TAJ. 22:172–175. 2009.
15	Kim JA, Kim DH, Hossain MA, Kim MY, Sung B, Yoon JH, Suh H, Jeong TC, Chung HY and Kim ND: HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells. Int J Oncol. 44:473–480. 2014.PubMed/NCBI
16	Gullett NP, Amin AR Ruhul, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ and Kucuk O: Cancer prevention with natural compounds. Semin Oncol. 37:258–281. 2010. View Article : Google Scholar : PubMed/NCBI
17	Mehta RG, Murillo G, Naithani R and Peng X: Cancer chemoprevention by natural products: How far have we come? Pharm Res. 27:950–961. 2010. View Article : Google Scholar : PubMed/NCBI
18	Cho YH, Yoon SY and Kim SN: Irinotecan monotherapy versus irinotecan-based combination as second-line chemotherapy in advanced gastric cancer: A meta-analysis. Cancer Res Treat. 49:255–262. 2017. View Article : Google Scholar : PubMed/NCBI
19	Kachalaki S, Ebrahimi M, Khosroshahi L Mohamed, Mohammadinejad S and Baradaran B: Cancer chemoresistance; biochemical and molecular aspects: A brief overview. Eur J Pharm Sci. 89:20–30. 2016. View Article : Google Scholar : PubMed/NCBI
20	Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Laurence J and Keefe DM: Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol. 64:123–132. 2009. View Article : Google Scholar : PubMed/NCBI
21	Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, Al-Dasooqi N and Keefe DM: Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol. 90:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
22	Kung HN, Weng TY, Liu YL, Lu KS and Chau YP: Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells. PLoS One. 9:e881222014. View Article : Google Scholar : PubMed/NCBI
23	Wei D, Zhang X, Zou H, Wang L, Fu B, Wu X, Luo Z, Li X, Ge J, Li Y, et al: WW domain containing oxidoreductase induces apoptosis in gallbladder-derived malignant cell by upregulating expression of P73 and PUMA. Tumour Biol. 35:1539–1550. 2014. View Article : Google Scholar : PubMed/NCBI
24	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
25	Sheta R, Woo CM, Roux-Dalvai F, Fournier F, Bourassa S, Droit A, Bertozzi CR and Bachvarov D: A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. J Proteomics. 145:91–102. 2016. View Article : Google Scholar : PubMed/NCBI
26	Feferman L, Bhattacharyya S, Deaton R, Gann P, Guzman G, Kajdacsy-Balla A and Tobacman JK: Arylsulfatase B (N-acetylgalactosamine-4-sulfatase): Potential role as a biomarker in prostate cancer. Prostate Cancer Prostatic Dis. 16:277–284. 2013. View Article : Google Scholar : PubMed/NCBI
27	Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, Schüll S, Andree M, Coutelle O, Yazdanpanah B, et al: Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 3:881–891. 2013. View Article : Google Scholar : PubMed/NCBI